Interferon Alpha-2a Treatment for Post-Uveitic Refractory Macular Edema
Interferon Alpha-2a Treatment for Post-Uveitic Refractory Macular Edema
复制标题
DOI：
10.1080/09273948.2019.1589526
复制
发表时间：
2019-04-29
影响因子：
3.3
通讯作者：
Cimino, L.
中科院分区：
文献类型：
--
作者：
De Simone, L.;Sangiovanni, A.;Cimino, L.
目的：观察干扰素（IFN）α-2a治疗葡萄膜炎后难治性黄斑水肿（ME）的疗效。方法：回顾性队列葡萄膜炎后难治性ME患者，接受皮下注射IFN α-2a至少3个月。将基线中心黄斑厚度（CMT）和最佳矫正视力（BCVA）与随访12个月时进行比较。结果：共纳入37例患者。治疗持续时间（中位数[四分位距]）为14[8-24]个月，随访时间为17[10-38]个月。CMT（平均值[标准差]）在1个月后从438[140] μ m降至335[119] μ m（p < 0.0001），并在12个月内保持显著降低（286[98] μ m，p = 0.001）。BCVA（基线时为0.48[0.33] logMAR）在12个月时改善了0.26[0.33] logMAR（p = 0.001）。复发14例。7例患者出现治疗副作用，无严重不良事件。结论：IFN α-2a治疗葡萄膜炎后难治性ME有效、安全、耐受性好。
Purpose: To assess the efficacy of interferon (IFN) alpha-2a in the treatment of post-uveitic refractory macular edema (ME). Methods: Retrospective cohort of patients with post-uveitic refractory ME, who received subcutaneous IFN alpha-2a injections for at least 3 months. Baseline central macular thickness (CMT) and best-corrected visual acuity (BCVA) were compared with those at follow-up visits up to 12 months. Results: Thirty-seven patients were included. Treatment duration (median [interquartile range]) was 14[8-24] months with a follow-up of 17[10-38] months. CMT (mean [standard deviation]) decreased from 438[140] to 335[119] mu m after 1 month (p < 0.0001) and remained significantly lower up to 12 months (286[98] mu m, p = 0.001). BCVA (0.48[0.33] logMAR at baseline) improved by 0.26[0.33] logMAR (p = 0.001) at 12 months. There were 14 recurrences. Seven patients had treatment side effects, without serious adverse events. Conclusions: IFN alpha-2a was effective, safe, and well tolerated in treating post-uveitic refractory ME.